insights

Microdosing Retatrutide (GLP-3): Chart, Schedules & Doses

Microdosing retatrutide (GLP-3) chart with weekly schedules, dosages & free calculator. Compare micro vs standard protocols based on half-life data.

Insulin syringe drawing micro-dose from retatrutide vial with dose splitting calendar and measurement tools

Last medically reviewed: 2026-06-08 by GLP3 Planner editorial. References inline as available.

← Retatrutide Hub All GLP-1 Microdosing →

Quick Answer: How to Microdose Retatrutide (GLP-3)

Microdosing retatrutide, referred to in peptide communities as GLP-3, means splitting your weekly dose into 2–3 smaller injections instead of one. For example, a 6mg weekly dose becomes 2mg every 2–3 days. This can reduce peak drug levels by 28–38%, potentially lowering nausea and other GI side effects. There are no clinical trials on this approach. It is based on pharmacokinetic modelling and community experience.

Key Takeaways

  • Microdosing could theoretically reduce peak-to-trough ratios by 28-38%, potentially minimizing side effects
  • Successful precedents exist with insulin and growth hormone therapies using similar principles
  • Mathematical models suggest maintained efficacy (~75-100%) with appropriate dose adjustments
  • No clinical trials have validated microdosing for GLP-1 agonists - all evidence is theoretical or anecdotal
  • 55% of microdosers make decisions without physician consultation, raising safety concerns

What Is Retatrutide Microdosing?

Retatrutide microdosing means splitting the once-weekly dose into smaller injections taken two to seven times a week. The total weekly amount stays the same; it's just spread across several days instead of landing in one shot. Retatrutide is an investigational triple-agonist (GLP-1, GIP, and glucagon) with a half-life of roughly 6 days (Coskun et al., Cell Metabolism, 2022). That slow clearance is what makes splitting plausible: the drug hangs around long enough that smaller, more frequent injections can hold blood levels steadier.

Can you microdose retatrutide? Mechanically, yes, and plenty of people do. But no clinical trial has tested it. Every retatrutide trial so far used once-weekly dosing, so the safety and effectiveness of any split schedule come from pharmacokinetic modelling and self-reported community experience, not trial data. If you're considering it, do it with a provider and use legitimately sourced medication. The sections below walk through the schedules, the modelling, and the tradeoffs.

Popular Retatrutide Microdosing Schedules Compared

Each schedule below uses our pharmacokinetic calculator to model a standard 12-week retatrutide (often called "reta") titration (2mg → 4mg → 8mg weekly equivalent) at different injection frequencies — see the standard retatrutide dosage chart for the base protocol. See how split dosing affects drug concentration stability.

Click any schedule to view the full interactive simulation with projected drug levels over time.

1. Standard Weekly Titration (Clinical Trial Baseline)

The once-weekly protocol from Phase 2 trials. This is the comparison baseline. Notice the characteristic "sawtooth" pattern with significant variation between injection days.

2mg → 4mg → 8mg/week • 1 injection/week • P/T Ratio: ~4.0

Drug concentration chart for standard weekly retatrutide titration View Full Interactive Schedule →

2. Twice Weekly Split Titration (Most Popular)

The most frequently adopted microdosing approach. Splitting each weekly dose into Monday/Thursday injections reduces peak concentration by ~28%, which may explain reports of reduced nausea.

1mg → 2mg → 4mg 2x/week • 2 injections/week • P/T Ratio: ~2.1 • Peak Reduction: 28%

Drug concentration chart for twice weekly split retatrutide titration View Full Interactive Schedule →

3. Three Times Weekly Titration (Mon/Wed/Fri)

A step beyond twice-weekly with ~35% peak reduction. The Monday/Wednesday/Friday schedule fits naturally into work-week routines with consistent 48-hour spacing.

~0.7mg → 1.3mg → 2.7mg 3x/week • 3 injections/week • P/T Ratio: ~1.6 • Peak Reduction: 35%

Drug concentration chart for three times weekly retatrutide titration View Full Interactive Schedule →

4. Daily Microdose Titration (Maximum Stability)

The flattest concentration curve with P/T ratio of ~1.2. Requires the most commitment (7 injections weekly) and is typically reserved for those highly sensitive to GLP-1 side effects.

~0.3mg → 0.6mg → 1.15mg daily • 7 injections/week • P/T Ratio: ~1.2 • Peak Reduction: 48%

Drug concentration chart for daily retatrutide microdose titration View Full Interactive Schedule →

5. Every Other Day Titration (EOD Protocol)

A practical middle ground between twice-weekly and daily. This 4x/week pattern (Mon/Wed/Fri/Sun) offers meaningful peak reduction (~30%) with half the injection burden of daily dosing.

0.5mg → 1mg → 2mg 4x/week • 4 injections/week • P/T Ratio: ~1.8 • Peak Reduction: 30%

Drug concentration chart for every other day retatrutide titration View Full Interactive Schedule →

6. Low-Dose Maintenance Protocol

Post-titration maintenance at 2mg/week (1mg twice weekly). Research on GLP-1 maintenance suggests this may preserve 75%+ of weight loss efficacy while reducing cost and side effect burden.

1mg 2x/week (flat) • 2 injections/week • P/T Ratio: ~2.1 • Use Case: Post-goal maintenance

Drug concentration chart for low-dose retatrutide maintenance protocol View Full Interactive Schedule →

Create Your Custom Microdosing Protocol

These pre-built schedules represent common approaches, but optimal dosing varies by individual. Use our free calculator to model any dose and frequency combination with real pharmacokinetic calculations.

Plotter

Reminder: Microdosing remains experimental with no clinical trial validation. These schedules are for educational modeling purposes only. Always consult with a qualified healthcare provider before modifying any prescribed medication regimen.

The Microdosing Hypothesis

Retatrutide (reta) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Like semaglutide and tirzepatide, it's designed for once-weekly injection, but a growing number of users are splitting their doses into smaller, more frequent injections instead.

The idea is straightforward: dividing the weekly dose into multiple injections could produce more stable drug levels, reduce side effects, and better approximate the body's natural hormone patterns. Here's what the available evidence actually shows.

The Pharmacokinetic Foundation

Understanding Peak-to-Trough Ratios

In pharmacokinetics, the peak-to-trough (P/T) ratio measures how much drug concentration varies between doses. A lower ratio means more stable levels, which theoretically translates to:

  • Consistent therapeutic effect: Steady drug levels maintain continuous receptor activation
  • Reduced side effects: Lower peak concentrations minimize adverse reactions
  • Better tolerability: Gradual exposure allows physiological adaptation

Mathematical modeling shows:

Weekly dosing P/T ratio: ~3.5-4.0
Twice-weekly dosing P/T ratio: ~2.0-2.5
Daily dosing P/T ratio: ~1.2-1.5

Peak reduction with split dosing: 28-38%
Trough increase with split dosing: 15-25%

The Triple Agonist Complexity

Retatrutide's unique triple mechanism adds layers of complexity to microdosing considerations:

  • GLP-1 receptors: Rapid desensitization may benefit from lower, more frequent activation for sustained weight-loss effects
  • GIP receptors: Different tissue distribution and kinetics than GLP-1
  • Glucagon receptors: Energy expenditure effects may vary with dosing pattern
  • Receptor balance: Unknown how split dosing affects the ratio of receptor activation

Lessons from Established Peptide Therapies

Insulin: The Original Microdosing Success

Insulin therapy provides the strongest precedent for peptide microdosing:

Traditional Approach:

  • NPH insulin twice daily
  • High P/T ratios
  • Frequent hypoglycemia
  • Poor glycemic control

Modern Microdosing:

  • Basal-bolus regimens
  • Continuous infusion pumps
  • Stable glucose levels
  • Reduced complications

The shift from infrequent large doses to frequent small doses dramatically improved diabetes outcomes. fewer hypos, better A1C, fewer long-term complications. It's the strongest precedent for dose-splitting in peptide therapy.

Growth Hormone: Daily Beats Weekly

Growth hormone replacement tells a similar story:

  • Physiological pattern: Natural GH secretion is pulsatile, primarily nocturnal
  • Clinical practice: Daily injections preferred over weekly despite longer-acting options
  • IGF-1 stability: Daily dosing maintains steadier IGF-1 levels
  • Side effect profile: Lower incidence of edema and joint pain with daily administration

Why GLP-1 Agonists Might Be Different

However, GLP-1 agonists have unique characteristics that complicate direct comparisons:

  • Engineered for extended action: Modified to resist degradation and extend half-life
  • Receptor desensitization: Tolerance develops regardless of dosing pattern
  • Clinical validation: All trials used weekly dosing, establishing safety and efficacy
  • Protein binding: >99% albumin binding creates natural depot effect

The Case for Microdosing: Potential Benefits

1. Side Effect Mitigation

The primary motivation for microdosing is reducing adverse effects:

Theoretical advantages:

  • Lower peak concentrations reduce nausea intensity
  • Gradual exposure allows GI adaptation
  • Reduced gastroparesis severity
  • Better maintenance of normal eating patterns

2. Metabolic Stability

More consistent drug levels could provide:

  • Steady appetite suppression: Avoiding the "feast-famine" cycle of weekly dosing
  • Consistent energy levels: Reduced fluctuation in metabolic rate
  • Better glucose control: Continuous incretin effect rather than peaks and valleys
  • Improved sleep: Less variation in nocturnal glucose and hunger hormones

3. Personalization Potential

Microdosing enables fine-tuning that weekly dosing cannot achieve:

  • Gradual titration: Smaller increments for sensitive individuals
  • Flexible scheduling: Adjust doses around life events
  • Rapid adjustment: Quicker response to side effects or inadequate efficacy
  • Combination strategies: Different doses on different days based on activity

4. Physiological Mimicry

Native GLP-1 secretion follows meal patterns, not weekly boluses:

Natural vs. Pharmacological:

• Natural GLP-1: Secreted 5-30 minutes after meals, returns to baseline within 2 hours
• Weekly injection: Sustained elevation for 168 hours with gradual decline
• Microdosing: Intermediate pattern with regular, smaller peaks

The Case Against: Significant Drawbacks

1. Lack of Clinical Evidence

Critical gaps in knowledge:

  • Zero randomized controlled trials on microdosing GLP-1 agonists
  • No long-term safety data for alternative dosing regimens
  • Unknown effects on cardiovascular outcomes
  • Potential for reduced efficacy not captured in models

2. Practical Challenges

Multiple injections create significant burden:

  • Injection fatigue: 3-7 injections weekly vs. one
  • Dose calculation: Splitting pens requires careful click counting
  • Storage concerns: Multiple partial pens in use
  • Travel complications: More supplies and refrigeration needs
  • Cost implications: Potential insurance coverage issues

3. Pharmacokinetic Uncertainties

Smaller doses may behave differently than expected:

  • Absorption variability: Smaller volumes may have different kinetics
  • Injection site effects: Multiple sites per week increase variability
  • Threshold effects: Minimum concentration needed for efficacy unknown
  • Receptor occupancy: May need sustained levels for full effect

4. Safety Concerns

Documented risks include:

  • Contamination risk with multiple pen entries
  • Dosing errors more likely with complex regimens
  • 55% of microdosers self-medicate without medical supervision
  • Use of non-FDA approved compounded formulations
  • 22% regret rate among microdosers

Mathematical Modeling: What the Numbers Say

Pharmacokinetic Simulations

Recent mathematical models using real-world pharmacokinetic data reveal:

Dosing Regimen Peak Level Trough Level P/T Ratio Efficacy*
Weekly (standard) 100% 25% 4.0 100%
Twice weekly 72% 35% 2.1 95%
Three times weekly 65% 40% 1.6 90%
Daily 52% 45% 1.2 75%

*Theoretical efficacy based on area under curve (AUC) maintenance

Key Modeling Insights

  • Diminishing returns: Daily dosing provides minimal additional benefit over 3x weekly
  • Efficacy threshold: Models suggest 75% efficacy retention even with daily microdosing
  • Individual variation: Fast metabolizers may benefit more from split dosing
  • Dose adjustment needed: Total weekly dose may need 10-20% increase with microdosing

Open-source availability: Researchers have made pharmacokinetic models publicly available at GitHub (seanlawley/glp1) for those interested in exploring dosing optimization strategies.

Community Experiences: Real-World Reports

The Microdosing Movement

Online communities have emerged around GLP-1 microdosing:

  • Reddit r/Peptides: 1,700+ members discussing microdosing strategies
  • Facebook groups: Multiple private groups with thousands of members
  • TikTok trends: #GLP1Hack videos with millions of views
  • Discord servers: Real-time support and protocol sharing

Reported Motivations

66%

Side effect reduction

38%

Cost savings

28%

Better control of blood sugar

Common Protocols Reported

While not medically validated, community members report using:

  • Monday/Thursday: Twice-weekly splitting for convenience
  • Monday/Wednesday/Friday: Three times weekly for stability
  • Every other day: Maximum smoothing of levels
  • Variable dosing: Higher doses on less active days

Concerning Trends

Problematic behaviors observed:

  • 55% make decisions without physician consultation
  • Many use compounded medications of uncertain quality
  • Dose escalation beyond FDA-approved limits
  • Combining multiple GLP-1 agonists
  • Following influencer protocols without medical oversight

A Personal Perspective

When I started reading the reta research, one thing bugged me: this triple-agonist mechanism is far more complex than semaglutide, yet the dosing protocol is identical: once weekly, same as everything else. Since I was already comfortable with multiple daily injections from other peptide protocols, I wanted to see if splitting the dose made a noticeable difference.

Like a lot of early adopters, I was after the minimum effective dose, enough appetite reduction to stay on track without killing my relationship with food. Complete appetite suppression at higher doses isn't something I wanted to deal with.

That's actually why I built GLP3Planner.com. While the tool models standard dosing protocols, it also enables users to explore "what-if" scenarios, including microdosing schedules. Being able to see how different dosing patterns change drug levels over time made the tradeoffs much clearer than reading PK papers ever did.

Important note: My personal experimentation should not be taken as medical advice. I work closely with my healthcare provider, get regular lab work, and carefully document all effects. This level of medical supervision is essential for anyone considering alternative dosing strategies.

The Path Forward: Research Priorities

Critical Studies Needed

Turning microdosing from speculation into evidence-based practice requires:

  1. Phase 2 dose-finding studies: Head-to-head comparison of dosing frequencies
    • Primary endpoint: Side effect incidence and severity
    • Secondary endpoints: Weight loss, glycemic control, quality of life
    • Duration: Minimum 26 weeks to assess steady-state effects
  2. Pharmacokinetic/Pharmacodynamic modeling: Advanced compartmental analysis
    • Receptor occupancy studies at different dosing frequencies
    • Biomarker correlation with clinical outcomes
    • Individual variation in optimal dosing patterns
  3. Long-term safety evaluation: Cardiovascular and metabolic outcomes
    • MACE events with alternative dosing
    • Antibody formation risk with frequent injections
    • Injection site reaction patterns
  4. Personalized medicine approaches: Identifying who benefits from microdosing
    • Genetic markers for drug metabolism
    • Clinical predictors of side effect susceptibility
    • Machine learning models for dose optimization

Emerging Technologies

Several technologies in development could eliminate the need for microdosing entirely:

  • Smart delivery systems: Implantable devices providing continuous release
  • Oral formulations: Daily pills eliminating injection burden
  • Ultra-long-acting versions: Monthly or quarterly administration
  • Combination patches: Transdermal delivery with multiple agonists
  • AI-driven dosing: Real-time optimization based on continuous monitoring

Making an Informed Decision

Questions to Consider

If you're contemplating microdosing, ask yourself:

Why am I considering this approach?

Side effect management? Cost? Control? Ensure your motivations align with realistic expectations.

Do I have appropriate medical supervision?

Regular monitoring, lab work, and physician collaboration are non-negotiable for experimental approaches.

Can I maintain the injection schedule long-term?

Multiple weekly injections require commitment. Consider your lifestyle and travel patterns.

Am I using legitimate medication?

Only FDA-approved formulations from licensed pharmacies should be considered.

Risk-Benefit Analysis

Potential Benefits:

  • Reduced nausea and GI side effects
  • More stable appetite control
  • Personalized dose optimization
  • Gradual adaptation possible
  • Theoretical efficacy maintenance

Known Risks:

  • No clinical safety data
  • Unknown long-term effects
  • Injection burden and errors
  • Potential reduced efficacy
  • Insurance/cost complications

The Bottom Line

The PK math behind microdosing reta is sound. Splitting doses does flatten concentration curves and reduce peaks. The problem is that zero clinical trials have tested whether this translates to fewer side effects or equivalent weight loss. It's plausible, but unproven.

People are drawn to microdosing for real reasons: nausea management, cost savings, and more control over their dose response. But 55% of microdosers are doing this without medical oversight, and many are using compounded formulations with variable quality. That's a real risk.

If you want to try split dosing, get a provider involved, use legitimate medication, and don't expect miracles. The standard weekly protocol has actual clinical data behind it. Microdosing doesn't, yet.

Medical Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, professional diagnosis, or treatment recommendations. GLP3 Planner does not endorse or recommend any specific dosing regimen outside of FDA-approved protocols. Always consult with qualified healthcare providers before making any changes to your medication regimen. Individual responses to medications vary significantly, and what works for one person may be harmful to another. The experimental nature of microdosing carries unknown risks that could include reduced efficacy, unexpected side effects, or long-term complications.

Related Articles

Retatrutide Complete Guide

Everything about the triple-agonist: mechanism, trials, dosing, and calculator.

Retatrutide Reconstitution Guide

Step-by-step guide to mixing compounded retatrutide with bacteriostatic water.

Microdosing GLP-1 Medications

Compare split-dosing strategies across all GLP-1 agonists.

Standard Retatrutide Dosing Guide

Clinical trial protocols and titration schedules for standard weekly dosing.

Understanding Pharmacokinetics

Master the science behind drug level calculations and steady-state concepts.

Microdosing Tirzepatide

Split-dosing protocols for Mounjaro and Zepbound.

Microdosing Semaglutide

Split-dosing protocols for Ozempic and Wegovy.

Frequently Asked Questions

Can you microdose retatrutide?

Yes, microdosing retatrutide (reta) is being explored by some users as an alternative to standard weekly dosing. This involves splitting the prescribed weekly dose into smaller, more frequent injections, typically twice weekly, three times weekly, or even daily. The goal is to maintain more stable drug levels and potentially reduce side effects like nausea. However, microdosing reta is not FDA-approved, has no clinical trial validation, and should only be considered under medical supervision. Our pharmacokinetic calculator can help you model different dosing schedules to understand how they affect drug concentration over time.

How do you microdose reta?

To microdose reta, you divide your total weekly dose into multiple smaller injections. The most common approaches are: twice weekly (Monday/Thursday) where you split your dose in half; three times weekly (Monday/Wednesday/Friday) where you divide by three; or daily microdosing with one-seventh of your weekly dose each day. For example, an 8mg weekly dose becomes 4mg twice weekly, 2.7mg three times weekly, or approximately 1.15mg daily. Use our GLP3 Planner calculator to model your specific protocol and see projected drug levels. Always consult with your healthcare provider before modifying any dosing schedule.

Is microdosing retatrutide better than standard dosing?

Whether microdosing retatrutide is "better" depends on individual goals and tolerance. Theoretical benefits include 28-38% lower peak concentrations (potentially reducing nausea and GI side effects), more stable appetite suppression, and gradual adaptation. However, drawbacks include no clinical validation, increased injection burden (3-7 shots vs. one weekly), potential for dosing errors, and theoretical 5-25% reduced efficacy. Standard weekly dosing has proven safety and efficacy data from Phase 2 trials. Microdosing may benefit those with severe side effects who can't tolerate standard dosing, but most people do well with the established protocol.

What is a retatrutide microdosing protocol?

A retatrutide microdosing protocol is a structured schedule for splitting doses across multiple injections per week. Common protocols include: the twice-weekly split (most popular), three-times-weekly for greater stability, every-other-day (EOD) for a balance of convenience and smoothing, and daily microdosing for maximum concentration stability. Each protocol maintains the same total weekly dose but distributes it differently. The six schedules shown above with interactive charts demonstrate how different protocols affect peak-to-trough ratios. A proper protocol also includes consistent timing, proper injection rotation, and regular monitoring with your healthcare provider.

What is microdosing retatrutide?

Microdosing retatrutide refers to taking very small, subtherapeutic doses of retatrutide with the goal of achieving certain effects while minimizing side effects. Retatrutide is a novel peptide-based medication under investigation for metabolic conditions such as obesity and type 2 diabetes. Microdosing practices are experimental and are intended to explore dose–response, tolerability, or potential benefits at doses below those used in clinical trials.

Why are people interested in microdosing retatrutide?

Interest in microdosing retatrutide stems from its mechanism of action and the potential metabolic benefits observed in early research. Retatrutide acts on multiple receptors involved in appetite regulation, energy expenditure, and glucose metabolism, aiding in weight-loss. Some individuals and clinicians consider microdosing to attempt symptom relief or metabolic modulation while reducing the incidence or severity of side effects commonly reported at full therapeutic doses, such as nausea, gastrointestinal upset, or injection-site reactions.

Is there scientific evidence supporting microdosing retatrutide?

There is limited to no robust, peer-reviewed evidence specifically supporting microdosing retatrutide. Most clinical data for retatrutide come from controlled trials using established dosing regimens designed to achieve therapeutic efficacy. Microdosing strategies have not been systematically studied in large clinical trials, so safety, efficacy, and long-term outcomes remain uncertain. Any claims about benefits from microdosing are largely anecdotal or extrapolated from pharmacology rather than proven in rigorous studies.

How does microdosing differ from standard dosing?

Standard dosing is based on clinical trials that determine the amount and frequency needed to produce a therapeutic effect. Microdosing uses substantially lower amounts, often a fraction of the tested therapeutic dose, and may involve different dosing intervals. The objective changes from achieving an established clinical effect to exploring lower-dose responses. This difference means results are unpredictable: lower doses may be ineffective, or they may produce partial effects with fewer side effects, but these outcomes are not guaranteed.

What are the potential risks of microdosing retatrutide?

Potential risks include unknown effectiveness, delayed access to effective treatment if microdosing is inadequate, unpredictable side effects, and interactions with other medications or underlying conditions. Because protocols for microdosing are not standardized, dosing errors can occur. Additionally, using medications outside approved or studied regimens carries legal and medical risks, and long-term safety at microdoses has not been established.

Can microdosing retatrutide reduce side effects?

Microdosing may reduce the incidence or intensity of some short-term side effects by exposing the body to lower levels of the drug. However, this is not guaranteed, and some side effects could persist even at lower doses. Tolerance and individual variability play major roles. Without clinical trials comparing side effect profiles across doses, it is impossible to predict reliably whether microdosing will meaningfully improve tolerability for a given person.

How should someone approach microdosing if they are considering it?

Anyone considering microdosing retatrutide should first consult a qualified healthcare professional. A clinician can review medical history, current medications, and overall treatment goals; advise on evidence and risks; and recommend monitoring strategies if a nonstandard dosing approach is pursued. It is important to use accurate dosing devices, obtain medication through legitimate channels, and have a plan for evaluating effectiveness and side effects.

Are there legal or ethical concerns?

Yes. Using retatrutide outside approved dosing regimens or without appropriate prescription oversight may breach local regulations, pharmaceutical guidelines, and ethical standards. Clinicians should follow regulatory guidance, and patients should avoid sourcing medication from unreliable suppliers. Ethical practice emphasizes evidence-based use and informed consent when deviating from standard treatment protocols.

What alternatives exist to microdosing retatrutide?

Alternatives include following evidence-based dosing regimens established in clinical trials, lifestyle interventions (diet, physical activity, behavioral therapy), approved medications for weight management or metabolic control, and participation in clinical trials studying retatrutide or other agents. Working with healthcare professionals to tailor treatment goals and select proven therapies is the safest approach.

Will microdosing save money?

Potentially, but with caveats. While some users report stretching medication supply, this often involves using lower total weekly doses, which may compromise efficacy and lead to increased blood sugar levels. Insurance typically won't cover alternative dosing schedules, potentially increasing out-of-pocket costs. The practice also risks medication waste from contamination or errors.

What do doctors think about microdosing?

Medical opinions vary widely. Some physicians support personalized approaches for patients with severe side effects, while others strictly adhere to FDA-approved protocols. Most express concern about the lack of clinical data and potential liability. Open communication with your healthcare provider is essential for finding a mutually acceptable approach.

Where can I find more reliable information?

Look for peer-reviewed journal articles, clinical trial registries, official prescribing information when available, and guidance from professional medical societies. Discuss questions with endocrinologists, obesity medicine specialists, or primary care providers. If interested in research participation, clinicaltrials.gov and institutional trial listings can provide legitimate opportunities to access investigational treatments under regulated conditions.

Is 1mg of retatrutide enough to see results?

In the Phase 2 clinical trial, the 1mg weekly group showed modest but measurable weight loss (approximately 8% at 48 weeks). While less dramatic than higher doses, 1mg still activates all three receptors (GLP-1, GIP, and glucagon). Many users start at 1mg to assess tolerance before titrating up.

What is the benefit of splitting retatrutide doses?

Splitting a weekly dose into multiple injections (e.g., two half-doses) can reduce peak drug levels and potentially minimize side effects like nausea, while maintaining similar average blood levels. Our half-life calculator lets you visualize the difference between once-weekly and split dosing to see how your levels change.